Literature DB >> 34825653

20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor.

René Lafont1,2, Maria Serova1, Blaise Didry-Barca1, Sophie Raynal1, Louis Guibout1, Laurence Dinan1, Stanislas Veillet1, Mathilde Latil1, Waly Dioh1, Pierre J Dilda1.   

Abstract

20-Hydroxyecdysone (20E) is a steroid hormone that plays a key role in insect development through nuclear ecdysteroid receptors (EcR/RXR complex) and at least one membrane GPCR receptor (DopEcR). It also displays numerous pharmacological effects in mammals, where its mechanism of action is still debated, involving either an unidentified GPCR or the estrogen ERβ receptor. The goal of this study was to better understand 20E mechanism of action in mammals. A mouse myoblast cell line (C2C12) and the gene expression of myostatin (a negative regulator of muscle growth) were used as a reporter system of anabolic activity. Experiments using protein-bound 20E established the involvement of a membrane receptor. 20E-like effects were also observed with angiotensin(1-7), the endogenous ligand of MAS. Additionally, the effect on myostatin gene expression was abolished by Mas receptor knock-down using siRNA or pharmacological inhibitors. 17β-Estradiol (E2) also inhibited myostatin gene expression, but protein-bound E2 was inactive, and E2 activity was not abolished by angiotensin(1-7) antagonists. A mechanism involving cooperation between the MAS receptor and a membrane-bound palmitoylated estrogen receptor is proposed. The possibility to activate the MAS receptor with a safe steroid molecule is consistent with the pleiotropic pharmacological effects of ecdysteroids in mammals and, indeed, the proposed mechanism may explain the close similarity between the effects of angiotensin(1-7) and 20E. Our findings open up many possible therapeutic developments involving stimulation of the protective arm of the renin-angiotensin-aldosterone system (RAAS) with 20E.

Entities:  

Keywords:  20-hydroxyecdysone (20E); G protein-coupled receptor (GPCR); MAS receptor; ecdysteroid; estrogen; muscle; myoblast; renin–angiotensin–aldosterone system (RAAS)

Mesh:

Substances:

Year:  2021        PMID: 34825653     DOI: 10.1530/JME-21-0033

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  2 in total

1.  Diversity-Oriented Synthesis Catalyzed by Diethylaminosulfur-Trifluoride-Preparation of New Antitumor Ecdysteroid Derivatives.

Authors:  Máté Vágvölgyi; Endre Kocsis; Márta Nové; Nikoletta Szemerédi; Gabriella Spengler; Zoltán Kele; Róbert Berkecz; Tamás Gáti; Gábor Tóth; Attila Hunyadi
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

2.  Challenges in the Development of Drugs for Sarcopenia and Frailty - Report from the International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force.

Authors:  M Cesari; R Bernabei; B Vellas; R A Fielding; D Rooks; D Azzolino; J Mariani; A A Oliva; S Bhasin; Y Rolland
Journal:  J Frailty Aging       Date:  2022
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.